Introduction
The RNA inhibitors best known in clinical use are mithramycin and actinomycin D. Both are derived from species of Streptomyces, and their most important place in medicine has been in the treatment of various testicular and renal tumours (Tan et al., 1959; Brown and Kennedy, 1965) . They are thought to exert their action by binding with the DNA chain, preventing RNA reduplication and thus blocking the synthesis of proteins and enzymes (Kirk, 1960) .
It was noted during the trials of mithramycin that among its side effects hypocalcaemia was prominent (Parsons et al., 1967) . This prompted Ryan and Schwartz (1969) 
Patients and Methods
The salient features of the four patients treated are shown in Table I . The three women were postmenopausal; the other carried out under toluene. Serum and urinary calcium concentrations were estimated by the method of Trinder (1960) . Serum and urinary phosphate concentrations were estimated by the method of Delsal and Manhouri (1958) . Serum alkaline phosphatase was measured by the method of King and Armstrong. Heat and urea stability of the enzyme throughout the study showed characteristics of skeletal phosphatase (Fennelly et al., 1969) . Urinary hydroxyproline content was estimated by the method of Prockop and Udenfriend (1960) .
Results
Biochemical results of drug administration are given in Table  II (Fig. 3) , a 47-year-old single man had a two-year history of pain in the back. X-ray examination showed marked Paget's disease of skull, pelvis, and spine, with partial collapse of the twelfth thoracic and fourth and fifth lumbar vertebrae. Serum alkaline phosphatase was 320 K.A. units, and urinary calcium and hydroxyproline were also raised at 335 and 266mg per 24 hours respectively, rising further after immobilization. He was treated with two courses of actinomycin D 2,500 Mg, each over five days with a 10-day interval. There was some improvement of back pain, associated with biochemical changes similar to those previously noted in Case 1. Toxicity.-The most troublesome side effects were nausea, vomiting, and depression. All, however, cleared rapidly after cessation of therapy.
Case 4.-A 74-year-old woman, with a 14-year history of Paget's disease localized to the skull, had impaired renal function with blood urea 60 mg/ 100 ml. When referred to us she was complaining of very severe headaches (Fig. 4) . Her blood pressure was 210/40 and she was in congestive cardiac failure. She had an easily palpable thrill and grade 4 bruit over the left temporal area. Cardiac failure was poorly controlled with digoxin, frusemide 80 mg. daily, and spironolactone 100 mg. daily. Because of the renal impairment and the use of frusemide, little reliance could be placed on her urinary levels (Tambyah and Lim, 1969 (Fig. 1) . Twelve days after the first course actinomycin D 1,000 Mug daily for two days was given; leucopenia of 2,900/mm3 developed, resolving over the next week. Pain was much improved seven days after the last dose and did not return until 12 weeks later, at which time serum alkaline phosphatase and urinary calcium had returned almost to pretreatment levels. Biochemical changes consisted of a transient fall in serum calcium and inorganic phosphate, accompanied by an immediate and lasting fall in urinary calcium and hydroxyproline and a gradual persistent fall in serum alkaline phosphatase.
Case 2.-This patient (Fig. 2) , a 62-year-old woman, had a twoyear history of left knee pain. The knee was radiologically normal, but there was an area of Paget's disease in the left side of the pelvis involving the hip joint, and it was thought that her pain was referred from here. Actinomycin D 2,500 Mg was administered over three days; she was symptom-free five-days later, but pain returned after six weeks. At this stage she had two injections of actinomycin D 500,ug with an eight-day interval; pain relief (Z5 500 
Discussion
The acute fall in urinary calcium and hydroxyproline persisted as long as the patients were followed in hospital. In the absence of treatment a continuing rise would have been expected in urinary calcium (Albright and Riefenstein, 1948) . The fall in serum inorganic phosphate was quite pronounced but the fall in serum calcium was not as marked as that reported following treatment with mithramycin. This effect lasted five to seven days after the end of drug therapy. A delayed, gradual fall in serum alkaline phosphatase has been previously recorded in immobilized patients (Albright and Riefenstein, 1948) ; however, the effect persisted in our patients after discharge, and was prolonged in the one who received actinomycin D as an outpatient. We are satisfied that the three women had a significant clinical improvement. The man had persistent back pain, but multiple collapsed vertebrae rendered continuing pain inevitable. The results produced by actinomycin D resembled those produced by mithramycin and were similar to those reported by Ryan and Schwartz (1969) . We are not yet certain that there is a striking difference in the duration of benefit from these drugs. The mechanism responsible for these changes remains uncertain. The fall in serum alkaline phosphatase levels would suggest decreased osteoblastic activity, while the reduction in urinary calcium excretion suggests diminished overall activity of Paget's process with reduction in osteolytic and osteoblastic activity. The fall in urinary hydroxyproline level would support the concept of a reduced bone turnover. How these changes are brought about is unknown. Albright and Riefenstein (1948) documented a progressive fall in serum alkaline phosphatase in an immobilized patient with Paget's disease; the relative immobilization involved while in hospital may account for at least some of the fall seen in our patients. At the same time they showed that immobilization leads to progressively increasing hypercalcaemia; hydroxyproline excretion was not studied, but our patients, before treatment, tended to show a pronounced rise in both urinary hydroxyproline and urinary calcium. The reversal of this trend by RNA inhibitor drugs was striking. 
L
It is known that actinomycin D blocks the action of parathyroid hormone on bone (Eisenstein et al., 1964; Rasmussen et al., 1964) while not interfering with its actions on renal calcium and phosphate handling. Actinomycin D does not prevent secretion of parathyroid hormone (Tashjiian, 1965) . It is possible that the RNA inhibitors act initially by preventing parathyroid hormone induced calcium release from bQne, leading to a fall in serum calcium with a resulting increase in parathyroid hormone secretion. This extra parathyroid hormone (unable to act on bone) could be responsible for hypophosphataemia and hypocalciuria, by an action on tubular reabsorption. This aspect may be clarified somewhat by parathyroid hormone assay and studies of renal phosphate clearance.
The similarities between the effects of actinomycin D on our patients, and mithramycin (Ryan and Schwartz, 1969) , and the actions of calcitonin in Paget's disease as described by Bijvoet and Jansen (1967) and Bijvoet et al. (1968) , suggest that RNA inhibitors may act by potentiating or stimulating the action of calcitonin. Calcitonin assay may shed some light on this aspect.
A direct action of RNA inhibitors on osteoblasts appears quite likely, particularly in view of the findings of reduced formation of chondroitin sulphate in rats treated with actinomycin D (Hulth and Lindberg, 1968) and the finding of inhibition of bone growth in children treated with this agent for renal tumours (Aarskog and Hexeberg, 1968) . However, the finding of such a pronounced fall in urinary calcium even after the serum calcium level has returned to normal suggests that a humoral mechanism is also likely to be involved.
Introduction
Tropical splenomegaly syndrome refers to chronic splenomegaly of uncertain cause which has been reported from a number of tropical countries (Pitney, 1968) . In Uganda the syndrome was formerly known as "big spleen disease" and has been associated with lymphocytic infiltration of the hepatic sinusoids (Hamilton et al., 1965 (Hamilton et al., , 1966 Marsden et al., 1965) . Malarial infection has been implicated in its aetiology on the basis of several kinds of indirect evidence. There is a close geographic coincidence of tropical splenomegaly syndrome with malarious areas, and patients having it show high titres of malaria antibodies (Gebbie et al., 1964; Hamilton et al., 1965; Marsden et al., 1967) . Sickle-cell trait, which confers considerable protection against severe Plasmodium falciparum malaria, occurs rarely if at all in these patients (Hamilton et al., 1969) . More compelling evidence is contained in the reports of improvement in hepatosplenomegaly and anaemia in patients with tropical splenomegaly syndrome following long-term malaria prophylaxis (Lowenthal and Hutt, 1968; Watson-Williams and Allan, 1968; Sagoe, 1970) . In order to confirm these reports a double-blind randomized clinical trial using primaquine and chloroquine was carried out in 29 Ugandan patients with tropical splenomegaly syndrome. The results form the basis of the present report.
